Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke
Επιτομή
Background: Low-density lipoprotein (LDL) cholesterol has been long associated with the risk for ischemic stroke, myocardial infarction, and cardiovascular death. For more than a decade, the main pharmacological option to prevent stroke and myocardial infarction through LDL-cholesterol lowering was the use of statins. During the recent years, two novel classes of drugs have proven their efficacy and safety to reduce LDL-cholesterol and prevent cardiovascular events in large, well-conducted randomized controlled trials: ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Aims: The present review summarizes the evidence arising from the latest trials of lipid-lowering treatment for cardiovascular outcomes prevention and discusses their implications for secondary prevention strategies in patients with ischemic stroke. Summary of review: There is strong evidence which confirms the hypothesis that the lower the LDL-cholesterol, the less frequent the cardiovascular events are and underlines the importance of treating our ischemic stroke patients with intensive statin treatment aiming at low LDL-cholesterol levels. The very low levels of LDL cholesterol seem to be safe, even in the mid/long term but longer follow-up data are needed. Currently there are no tools to reliably predict cardiovascular outcomes in the specific population of ischemic stroke patients. Conclusions: Stroke physicians should aim for low LDL-cholesterol levels by intensive statin treatment in all ischemic stroke patients. For those patients who are at the highest risk for recurrent stroke or another cardiovascular event and have unacceptable LDL-cholesterol levels despite intensive statin treatment, PCSK9 inhibitors should be considered. © 2019 World Stroke Organization.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
Bahls M., Lorenz M.W., Dörr M., Gao L., Kitagawa K., Tuomainen T.-P., Agewall S., Berenson G., Catapano A.L., Norata G.D., Bots M.L., van Gilst W., Asselbergs F.W., Brouwers F.P., Uthoff H., Sander D., Poppert H., Hecht Olsen M., Empana J.P., Schminke U., Baldassarre D., Veglia F., Franco O.H., Kavousi M., de Groot E., Mathiesen E.B., Grigore L., Polak J.F., Rundek T., Stehouwer C.D.A., Skilton M.R., Hatzitolios A.I., Savopoulos C., Ntaios G., Plichart M., McLachlan S., Lind L., Willeit P., Steinmetz H., Desvarieux M., Ikram M.A., Johnsen S.H., Schmidt C., Willeit J., Ducimetiere P., Price J.F., Bergström G., Kauhanen J., Kiechl S., Sitzer M., Bickel H., Sacco R.L., Hofman A., Völzke H., Thompson S.G., on behalf of the PROG-IMT Study Group (2020)Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for ... -
Impact of flavonols on cardiometabolic biomarkers: A meta-analysis of randomized controlled human trials to explore the role of inter-individual variability
Menezes R., Rodriguez-Mateos A., Kaltsatou A., González-Sarrías A., Greyling A., Giannaki C., Andres-Lacueva C., Milenkovic D., Gibney E.R., Dumont J., Schär M., Garcia-Aloy M., Palma-Duran S.A., Ruskovska T., Maksimova V., Combet E., Pinto P. (2017)Several epidemiological studies have linked flavonols with decreased risk of cardiovascular disease (CVD). However, some heterogeneity in the individual physiological responses to the consumption of these compounds has ... -
Serum lipid abnormalities in migraine: A meta-analysis of observational studies
Liampas I., Mylonas K.S., Brotis A., Dervenis P., Siokas V., Mentis A.-F.A., Dastamani M., Aloizou A.-M., Tsouris Z., Aslanidou P., Bakoyiannis C., Dardiotis E. (2021)Background: The association of migraine with vascular comorbidities is long-established. The contribution of the “traditional” cardiovascular risk factors to this connection remains unclear. Objective: To determine-quantify ...